Skip to main content
Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.
- Author(s): Ray, Lara A;
- Courtney, Kelly E;
- Ghahremani, Dara G;
- Miotto, Karen;
- Brody, Arthur;
- London, Edythe D
- et al.
Published Web Locationhttps://pubmed.ncbi.nlm.nih.gov/24949564/
No data is associated with this publication.
RationaleHeavy drinking smokers constitute a sizeable and hard-to-treat subgroup of smokers, for whom tailored smoking cessation therapies are not yet available.
ObjectiveThe present study used a double-blind, randomized, 2 × 2 medication design, testing varenicline alone (VAR; 1 mg twice daily), naltrexone alone (NTX; 25 mg once daily), varenicline plus naltrexone, and placebo for effects on neural activation to cigarette cues in a sample (n = 40) of heavy drinking daily smokers (≥10 cigarettes/day).
MethodsAll participants were tested after a 10-12-day titration period designed to reach steady state on the target medication. Participants underwent functional neuroimaging (fMRI) for examination of brain responses to visual smoking-related (vs. neutral) cues.
ResultsRegion of interest (ROI) analyses of brain responses to Cigarette vs. Neutral Cues indicated that the combination of VAR + NTX was associated with reduced activation of the bilateral anterior cingulate cortex as compared to placebo and to NTX alone. Exploratory whole-brain analyses also indicated significant differences in brain activation during cigarette cues in the active medications versus placebo condition. All medications suppressed left nucleus accumbens activation relative to placebo, suggesting the possibility that both medications, either alone or in combination, reduce neural signals associated with appetitive behavior.
ConclusionsAlthough preliminary, these neuroimaging findings indicate that clinical studies of the combination of VAR + NTX for heavy drinkers trying to quit smoking may be warranted.
Item not freely available? Link broken?Report a problem accessing this item